about
New SPECT and PET radiopharmaceuticals for imaging cardiovascular diseaseMyocardial viability in patients with ischemic cardiomyopathy-evaluation by 3-D integration of myocardial scintigraphic data--and coronary angiographic data.Carpe Datum: A Consideration of the Barriers and Potential of Data-Driven PET Innovation.2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.Regional myocardial perfusion defects during exercise, as assessed by three dimensional integration of morphology and function, in relation to abnormal endothelium dependent vasoreactivity of the coronary microcirculationRole of PET in the evaluation and understanding of coronary physiology.Anti-apolipoprotein A-1 IgG levels predict coronary artery calcification in obese but otherwise healthy individuals.Structural alterations of the coronary arterial wall are associated with myocardial flow heterogeneity in type 2 diabetes mellitus.Diagnostic value of PET-measured heterogeneity in myocardial blood flows during cold pressor testing for the identification of coronary vasomotor dysfunction.Effect of hormone replacement therapy on vasomotor function of the coronary microcirculation in post-menopausal women with medically treated cardiovascular risk factors.Improvement in coronary endothelial function is independently associated with a slowed progression of coronary artery calcification in type 2 diabetes mellitus.Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health.The influence of insulin resistance, obesity, and diabetes mellitus on vascular tone and myocardial blood flow.Quantitative PET/CT measures of myocardial flow reserve and atherosclerosis for cardiac risk assessment and predicting adverse patient outcomes.Impact of obesity and bariatric surgery on metabolism and coronary circulatory function.Quantitative assessment of myocardial blood flow--clinical and research applications.Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation.Positron-emitting myocardial blood flow tracers and clinical potential.Cardiac PET/Computed Tomography Applications and Cardiovascular Outcome.Pathophysiology of ST-segment elevation myocardial infarction: novel mechanisms and treatments.Myocardial blood flow: Putting it into clinical perspective.Cardiovascular PET/MR imaging: Quo Vadis?Potential Role of Cardiovascular Imaging in Improving Cardiovascular Outcome in Coronary Artery Disease.Role of risk stratification by SPECT, PET, and hybrid imaging in guiding management of stable patients with ischaemic heart disease: expert panel of the EANM cardiovascular committee and EACVI.3D assessment of myocardial perfusion parameter combined with 3D reconstructed coronary artery tree from digital coronary angiograms.Positron Emission Tomography-Determined Hyperemic Flow, Myocardial Flow Reserve, and Flow Gradient-Quo Vadis?Inflammatory cardiovascular risk biomarkers: update on novelties and limitations.Combined evaluation of myocardial perfusion and coronary morphology in the identification of subclinical CAD. Radiation exposure of 13N-ammonia PET/CT.Assessment of myocardial matrix expansion with cardiac magnetic resonance: entering a new area of cardiac risk stratification in type 2 diabetes mellitus?Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function.PET-measured heterogeneity in longitudinal myocardial blood flow in response to sympathetic and pharmacologic stress as a non-invasive probe of epicardial vasomotor dysfunction.Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus.Long-term survival of patients with viable and nonviable aneurysms assessed by 99mTc-MIBI SPECT and 18F-FDG PET: a comparative study of medical and surgical treatment.Effect of Diffuse Subendocardial Hypoperfusion on Left Ventricular Cavity Size by 13N-Ammonia Perfusion PET in Patients With Hypertrophic Cardiomyopathy.Comparison of two software systems for quantification of myocardial blood flow in patients with hypertrophic cardiomyopathy.Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.People’s corner award: Heinrich R. Schelbert MD, PhD, receives Distinguished ACC Lifetime Achievement Award.Schelbert receives ACC award.Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity: A Translational Approach.Correction to: Comparison of two software systems for quantification of myocardial blood flow in patients with hypertrophic cardiomyopathy.
P50
Q27011866-3857B246-9D17-4620-8457-E84A726B9B39Q30938321-CBE88C02-40E2-4B76-93D9-06B3CEC63706Q31010691-70241391-63A3-4CC2-8E5A-4D814AB360CFQ34436061-0E59AB50-AF7C-4FD3-AC8E-5DD482516F3BQ35581117-BB3A1DB7-A0B7-417B-9419-42416AEAA14FQ36017117-0035AED2-9837-42CD-892C-9417EF23A1EAQ36431826-927320F3-76A8-4B2A-9452-F63FEE0E40D6Q37242235-FF2708B5-DBEA-46C3-92FC-6494477EE990Q37277653-A073E575-8F66-4B69-8549-E0C6AE6B5186Q37291507-8092DFB6-AB62-450A-B685-90FDD1F1588BQ37473215-96215E70-0EBF-48F9-86B2-44745BDFF354Q37764498-48163328-52B3-43E9-A997-2EF4BA690D7EQ37972078-5BF33BAA-4DFB-4226-90EB-3A709561B69FQ38080503-C0C416E7-A9BE-4F2F-9A0F-F98231DC68E7Q38166678-C69D30BF-77E0-41FD-A2AD-0E913575CF43Q38221797-8342392C-470E-4F79-89A8-D311E557B464Q38322573-80D612FF-8099-4D17-B1A4-A02FAE7DC8E3Q38338510-BE220832-AA1E-4559-A98F-34DDF5FC9844Q38534530-FC54FE4E-E71B-4F59-A661-2BAD84FED76FQ38626782-C175F413-4C7C-4DA5-8449-4FEF1CBF5C8CQ38681519-75FF3B39-DBD8-426D-ACA6-E9172ABF9CCBQ38818566-04AF489E-2F81-45CA-A7B0-2B95F009088CQ38831128-5BBBBDBF-DA38-4A0C-956B-F74332021C50Q39015173-6C6E3F2C-198F-48A1-A992-12F50737B818Q39538210-6CA0AF3E-2FF9-4F82-92B5-A8FD82D0D870Q41024129-CDE31A08-783C-4FA8-8A22-D6DAD44E54FFQ42830261-B02380D7-3E3B-490D-965C-1FCC369026E0Q42954569-0DE83923-7E25-416A-912B-432F2B0584F1Q44772503-82AD2A55-DDF0-48F4-A1A2-03E576BA1304Q45995165-6A305C40-2D41-47E0-9990-C1FAD926E47AQ46119284-A1D1BE4C-4396-4F87-A195-CA561E1C8537Q46455337-5CF74334-A4DB-4EC7-BD4B-0656DDF37551Q46480039-C2099985-BB16-4D42-8F46-BCBC57356652Q47264703-5602D2B1-9370-4A66-83DD-8FEBFB61F516Q47557715-CAD4F92A-5A73-4151-AB6A-54207B22B977Q47804552-9A45873B-832B-428B-82E0-611B5B89BF65Q47994240-6E10926D-916B-4D42-9143-64E8105B3E91Q48290618-F2C22660-2918-450F-A284-724458B53195Q48499558-EF67A95F-8E3A-4DC7-91C2-BD8C0F9F97CDQ48503319-EC856846-85B0-4D88-A1E5-E5DCC6664A6D
P50
description
researcher
@en
wetenschapper
@nl
name
Schindler TH
@nl
Thomas Hellmut Schindler
@en
type
label
Schindler TH
@nl
Thomas Hellmut Schindler
@en
altLabel
Schindler TH
@en
prefLabel
Schindler TH
@nl
Thomas Hellmut Schindler
@en
P106
P31
P496
0000-0002-2141-7716